U.K., EU eye FDA's findings on Ranbaxy plant; J&J psoriasis med poised for $1.4B in 2014; Ohio docs fined for importing unapproved cancer meds;

@FiercePharma: Our newest publication, FiercePharmaMarketing, is now live at fiercepharmamarketing.com. All marketing, all the time. | Follow @FiercePharma

@TracyStaton: FDA approval, check. Now Teva has to woo patients to new longer-acting Copaxone. Story | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: And here's the rundown from @TracyStaton on what the new pub has in store. Item | Follow @CarlyHFierce

> EU and U.K. regulators are reviewing the FDA's findings on Ranbaxy's Toansa plant, subject of the latest enforcement action by the U.S. agency. Report

> Decision Resources figures that Johnson & Johnson's ($JNJ) new psoriasis drug Stelara will leap to the front of the line among systemic treatments, with $1.4 billion in sales next year. Release

> Seven Ohio oncologists were ordered to pay nearly $2.6 million in fines for importing unapproved cancer drugs into the U.S. Report

> Ireland's Minister for Finance plans to meet with top Regeneron ($REGN) executives in New York this week about a planned €220 million investment in the country. Report

> Novo Nordisk ($NVO) and a group of London hospitals are teaming up to develop a new model of patient-centered, specialty diabetes management. Report

Medical Device News

@FierceMedDev: Hydrogel with tiny capsules could control the release of drugs. More from FierceDrugDelivery | Follow @FierceMedDev

@MichaelGFierce: Nanodiamonds covered in silk promise smoother drug delivery. Story | Follow @MichaelGFierce

@EmilyWFierce: GenePeeks lets women get a closer look at potential donors' DNA, predict risk for disease in hypothetical child. Article | Follow @EmilyWFierce

@GalenMoore: Wait times for a doctor's appointment are longest in Boston, shortest in Dallas, survey says. Survey | Follow @GalenMoore

> Abbott slashes jobs at corporate headquarters. More

> Illumina's sales soar 24% with sights set on a big 2014. Story

> Medtronic's stent graft follows Gore's into aortic dissections with FDA approval. News

Biotech News

@FierceBiotech: IPO hopefuls look to extend biotech's window with $123M in fresh pitches. More | Follow @FierceBiotech

@JohnCFierce: Amgen extends PhIII sweep with more promising results for PCSK9 drug. Story | Follow @JohnCFierce

@DamianFierce: Novartis races to the FDA with its 'breakthrough' lung cancer drug. More | Follow @DamianFierce

@EmilyMFierce: Yesterday's issue of FierceBiotech Research featured microbiota and virus-free stem cells. Check it out here. | Follow @EmilyMFierce

> AstraZeneca is cutting 168 jobs as it shutters an Indian R&D site. News

> Merck's allergy pill sways an FDA panel but faces a long road to success. Article

Drug Delivery News

> Hydrogel with tiny capsules could control the release of drugs. Story

> URI scientist collects $1.3M to blast tumors with nanoparticles. More

> Nanodiamonds covered in silk promise smoother drug delivery. Article

> Nanogold 'superstructures' are held together with DNA for cancer drug delivery. News

> Evoke Pharma's nasal spray outdoes oral generic for diabetes-related stomach disease. Piece

> Artificial pancreas news: U.K. researchers unveil device, Animas snags Canadian approval of closed-loop system. Item

Diagnostics News

> Fluidigm is acquiring DVS in a $208M single-cell technology buyout. Story

> MDxHealth teams up with Teva to distribute its prostate, brain cancer tests. Article

> Will the real $1,000 genome please stand up? Story

> Epic Sciences teams with LabCorp to push its cancer diagnostic. News

> Nanostring grabs $55M in a follow-on offering. Article

> DioGenix's multiple sclerosis test hits the mark in a study. Item

Pharma Marketing News

> J&J persuades LA Supreme Court to toss $257M Risperdal marketing verdict. Story

> FDA approval, check. Now Teva has to woo patients to new, longer-acting Copaxone. News

> J&J tops 2013 journal-ad ranks with millions in print support for Invokana, Xarelto. Article

> Vivus, Arena hope Aetna weight-management program boosts diet-drug sales. Piece

> Priligy maker Menarini puts rugby players on cinema screens in premature-ejaculation awareness push. Item

And Finally... Belgium's UCB has launched a competition to find "superhumans" with unusual characteristics, believing genetic differences could identify new drug-development targets. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.